Last reviewed · How we verify
RBAK therapy
RBAK therapy involves the use of a specific combination of medications to treat various conditions.
RBAK therapy involves the use of a specific combination of medications to treat various conditions. Used for Acute myeloid leukemia (AML).
At a glance
| Generic name | RBAK therapy |
|---|---|
| Also known as | rabeprazole, amoxicillin, clarithromycin, bismuth subcitrate |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of RBAK therapy is not well-documented, but it is believed to work by targeting multiple pathways to achieve its therapeutic effects.
Approved indications
- Acute myeloid leukemia (AML)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |